ArticleClinical rheumatology2025
Subclinical sensorineural hearing loss in systemic lupus erythematosus: a comparative cross-sectional study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic lupus erythematosus (SLE) is a multisystem autoimmune disease that damages multiple target organs, including the ear. This study aims to determine the prevalence of hearing loss in patients with a confirmed diagnosis of SLE compared to controls and to assess frequency-specific hearing thresholds using extended audiometry (500 to 16,000 Hz).
methodsThis comparative cross-sectional study included 75 patients diagnosed with SLE and 150 matched control subjects. All subjects underwent otolaryngological evaluation, conventional and extended audiometry (500 to 8,000 and 10,000 to 16,000 Hz, respectively), and tympanometry.
resultsPatients with SLE showed a higher prevalence of sensorineural hearing loss (SNHL) at all frequencies and elevated thresholds at very high frequencies compared to the controls (p < 0.05). The most affected rage was 10-16 kHz, with an average threshold of 24.7 dB (IQR 13.1 - 44.4) and a SNHL prevalence of 50.7% in patients with SLE vs. 9.3% and 18.7% in both control groups (p < 0.001). Multivariate analysis showed that being a patient with SLE (OR = 10.84; p < 0.001) and older age (OR = 1.13/year; p < 0.001) were independent predictors of SNHL. In the SLE subgroup, age remained the only significant predictor (OR = 1.16; p < 0.001).
conclusionPatients with SLE have higher odds of developing SNHL compared to healthy controls and demonstrate a significantly increased prevalence of SNHL, particularly at very-high frequencies, which can only be detected through extended audiometry. These findings underscore the utility of extended audiometry in early detection of subclinical SNHL. Key Points • Patients with SLE shows a higher prevalence of SNHL, especially in very-high frequencies. • Patients with SLE demonstrated increased hearing thresholds when compared to control groups, particularly in very-high frequencies. • No significance was identified when compared chloroquine use and SNHL prevalence. • SLE and age were significant predictors of SNHL, whereas comorbidities, disease activity, and treatment were not.
Indexed as
Identifiers
40445520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.